Disclosure Statement. Hepatitis C. HIV/HCV Co-infection. Major Hepatitis Viruses. Hepatitis: definition. Hepatitis C and HIV/HCV Coinfection 1
|
|
- Nora Gallagher
- 6 years ago
- Views:
Transcription
1 Disclosure Statement Hepatitis C and HIV/HCV Co-infection No conflicts of interest exist between the speaker and any entity No endorsements of any products based on bias exist with the speaker Dell Robertson, PharmD, MHA Florida A&M University College of Pharmacy and Pharmaceutical Sciences Division of Director of Pharmacy Practice Hepatitis: definition Major Hepatitis Viruses Inflammation of the liver caused by many different agents, including: Viruses (A through E) Alcohol Drugs/prescriptions Herbs Genetic disorders Obesity (NASH) Virus Hepatitis A Hepatitis B Hepatitis C Means of transmission Fecal-oral: Contaminated food or water Sexual, mother-to-child, blood exposure (transfusion, IDU, tattoo) Blood exposure (transfusion, IDU, tattoo); sexual, mother-to-child less common Hepatitis C and HIV/HCV Coinfection 1
2 Hepatitis C: A Global Health Problem Million (M) Carriers Worldwide Hepatitis C: United States United States 3-4 M Americas M Western Eastern Europe Europe 5 M 10 M Africa M Far East Asia 60 M Southeast Asia M Australia 0.2 M 3.7 million infected in U.S. (1.8% of population) 25,000-35,000 new infections per year Sixty percent due to injection drug use (IDU) A leading cause of cirrhosis and liver cancer and the most common reason for liver transplantation in the United States 8,000-10,000 deaths from HCV annually HCV-related deaths and transplants projected to triple in next decade World Health Organization. Weekly epidemiological record. 2009;74: CDC. MMWR. 2008; 47(No. RR-19):1-39. NIH Consensus Development Conference Panel Statement Management of Hepatitis C, 2004 Prevalence of HCV infection in selected subgroups in the U.S. Risk factors for Hepatitis C infection Injection drug users: 52-90% Hemophiliacs: 60-85% HIV infected individuals: 9-40% incarcerated HIV+: 50% MSM: 4-8% IVDU 10% Cocaine 10% Exposure to infected 20% 55% sex partner or multiple partners Occupational, hemodialysis, 5% household, perinatal No recognized source modes; 2010 Hepatitis C and HIV/HCV Coinfection 2
3 Natural History of Hepatitis C Most patients with chronic HCV infection are asymptomatic years Acute Hepatitis C Chronic Hepatitis 75%-85 % Cirrhosis 20 % Acute Infection Symptoms may present 4-12 weeks after exposure Most patients are asymptomatic and rarely progress to fulminant disease Most common symptoms malaise, weakness, anorexia, and jaundice Hoofnagle JH Hepatology. 1997;26 (suppl 1): 15S-20S Di Bisceglie, Hepatology, 2000 Chronic Infection Defined as the presence of viral RNA in the serum 6 months or more after initial infection Associated with the long term development of end stage liver disease, cirrhosis, or HCC. Concurrent Alcohol use most likely leads to complications and end stage liver disease Co Infection with HIV increases the probability of developing HCC Hepatitis C: Pathophysiology Hepatitis C virus (HCV) replicates in liver cells (hepatocytes) Immune system responds with inflammation Inflammation leads to fibrosis and eventually, in some cases, cirrhosis (scarring) Hepatitis C and HIV/HCV Coinfection 3
4 Complications of Cirrhosis Edema Dangerous impairment of liver function Inability to clear toxins from the circulation => jaundice; hepatic encephalopathy Inability to synthesize key proteins (albumin, clotting factors) Cancer (hepatocellular carcinoma)- HCC Blockage of portal vein blood flow through the liver, leading to ascites Bacterial peritonitis (infection of the ascites) Esophageal varices Ascites Other Extrahepatic Manifestations of Hepatitis C Hematologic: Cryoglobulinemia lymphoma Rheumatologic: rheumatoid arthritis Renal: Glomerulonephritis Dermatologic: Porphyria cutanea tarda Cutaneous necrotizing vasculitis Lichen planus CNS: depression Systemic: fatigue Management of Hepatitis C. NIH Consensus Statement, Hepatitis C and HIV/HCV Coinfection 4
5 Diagnostic Approach: Elevated ALT Levels with Risk Factors for HCV Negative <5% chance of hepatitis C Elevated ALT levels + risk factors for hepatitis Anti-HCV (EIA) testing Positive Diagnosis of hepatitis C>95% certain Refer to specialist for evaluation and treatment Hepatitis C: Diagnosis Antibody test (EIA) Indicates past or active infection Unlike hepatitis B, presence of antibodies does not confer immunity HCV RNA test (PCR) Confirms active infection, infectivity to others Quantitative or qualitative RNA tests exist; the former is more often used because it provides a potentially useful viral load measurement Predictors of Advanced Disease Person infected years Person with long history of moderate to high alcohol consumption Lab values that suggest cirrhosis: low platelets, low albumin, high bilirubin, AST level higher than ALT level Liver Biopsy Provides information regarding Degree of inflammation Stage of fibrosis or scarring Presence/absence of cirrhosis Helps determine Prognosis Cause of liver disease Need for treatment Hepatitis C and HIV/HCV Coinfection 5
6 Predictors of Virologic Response Viral Factors Host Factors Types of Hep C Hepatitis C has six major types called genotypes Genotype Viral Load Age Cirrhosis Race Gender Weight Genotype 1: by far the most common type in the US. Genotype 2, 3, or 4: needs six months of treatment Hepatitis C Treatment Decisions Do not treat patients with Advanced cirrhosis Severe depression/psychiatric disorder Low blood counts Thyroid disease, untreated Autoimmune diseases Alcohol/drug dependency Pregnancy Treatment Outcomes RVR: Rapid Virologic Response, Undetectable HCV RNA at week 4 of treatment EVR: early viral response, undetectable at 12 weeks, > 2 log reduction from baseline ETR: end of treatment response: undetectable at end of treatment 24 or 48 week course, depending on genotype SVR: undetectable 6 months after tx. Complete IL28B genotyping for GT1 predicts response to therapy Hepatitis C and HIV/HCV Coinfection 6
7 Recommended Standard Therapy Pegylated interferon- IV [IFN] Ribavirin- 200 mg tablets (Copegus), [RBV] Oral Protease Inhibitors for Chronic HCV Telaprevir-Incivek [TVR] Boceprevir- Victrelis [BOC] Simeprevir- Olysio [SMV] Sofosbuvir- Solvadi [SOF] Hepatitis C PEGYLATED INTERFERON Pegylated interferon Complexed w/polyethylene glycol (PEG) More stable blood levels, thus more effective Weekly injection Better compliance? ( regular interferon was dosed 3x per week!) Side effects similar Prevention of Chronic Infection or maintain a Sustained Virologic Response (SVR) in Chronic Infection Treatment Goals Sustained Virologic Response Rates Prevent progression of scarring Eradicate virus Prevent complications of end stage liver disease % Patie ents 60% 40% 20% 30% n = % n = % n = 453 0% PEG-IFN IFN + RBV PEG-IFN + RBV Fried MW et al. DDW Hepatitis C and HIV/HCV Coinfection 7
8 ients % of Pati Sustained Response According to Genotype 21% n = 145 PEG-IFN IFN + RBV 37% n = % n = % n = 69 61% n = 145 Genotype 1 Genotype 2, 3 PEG-IFN + RBV 76% n = 140 Fried MW et al. DDW Side Effects of Interferon Flu-like symptoms Alopecia Headache Thyroiditis Fatigue or asthenia Myalgia, arthralgia Nausea Fever, chills Diarrhea Neuropsychiatric disorders Depression Mood lability Brain Fog Injection-site reaction Lab alterations Neutropenia Anemia Thrombocytopenia PEGASYS (peginterferon alfa-2a) [package insert]. Nutley, NJ: Hoffmann-La Roche; PEG-Intron (peginterferon alfa-2b) [package insert]. Kenilworth, NJ: Schering Corporation; Side Effects of Ribavirin Hemolytic anemia Teratogenicity Cough and dyspnea Rash and pruritus Insomnia Anorexia Hepatitis C INTERFERON AND RIBAVIRIN Serious, less common side effects Bacterial infections Thyroid disease Se ere depression s icide Severe depression, suicide Seizures Vision or hearing loss Kidney or heart failure Fetal abnormalities/fetal loss COPEGUS (ribavirin, USP) [package insert]. Nutley, NJ: Hoffmann-La Roche; Hepatitis C and HIV/HCV Coinfection 8
9 Hepatitis C INTERFERON AND RIBAVIRIN Requirements of treated patients 6-12 month course Monitoring For side effects: visits and blood tests at 2 and 4 wks, then every 1-3 months For effectiveness: recheck viral level at 6 and 12 months Monitoring the Patient Anemia Bone marrow toxicity Pulmonary disorders Pancreatitis Psychiatric Side Effect Management Aggressive management of side effects increases compliance and treatment success. Anti-depressants depressants, anti-nauseanausea and insomnia meds are helpful. Growth factors: erythropoetin and filgastim are helpful. (off label use) Management of Fatigue Conduct baseline assessment Check hydration status and diet Advise patients t to: Avoid strenuous activities, incorporate relaxing activities in daily regimen Plan lighter activities for days after interferon dosing Hepatitis C and HIV/HCV Coinfection 9
10 Management of Depression Assess before starting treatment Stabilize on antidepressant before treatment Establish care with counselor, psychiatrist, primary care giver before treatment Immediate evaluation if suicidal. May need to discontinue treatment. Management of Cough Assess for pneumonia Rule out other causes (eg, allergies, bronchial infections) Advise patients to: Increase daily fluid intake, use humidifier, use cough drops or nonsedating cough medications Hep C and HIV Topics Interactions of viruses Treatment decisions Drug interactions Hepatitis C HIV/HCV COINFECTION 10%-30% w/ HIV also have HCV Rate of HCV depends on risk factor Hemophiliacs >90% IDUs 70%-90% MSM 5%-10% Hepatitis C and HIV/HCV Coinfection 10
11 HCV/HIV Coinfection HIV accelerates Hep C liver disease (may cut time to cirrhosis in half!) Hep C may impair immune reconstitution after HAART HCC may occur at an earlier age with coinfection Hepatitis C HIV/HCV COINFECTION HCV liver disease is more severe in HIV+ HCV liver disease is now more important HIV deaths are decreasing Deaths related to liver disease are increasing Effect of HCV infection on HIV/AIDS progression is not known Hepatitis C HIV/HCV COINFECTION HIV treatments can cause liver problems/liver enzyme elevations In some studies these liver problems are increased in those w/hcv Some report worsening of HCV liver disease after HIV treatment is started HIV/HCV Treatment Predictors of success in achieving a sustained viral response: CD4 count greater than 500 HIV RNA levels below 10,000 copies No alcohol consumption Hepatitis C and HIV/HCV Coinfection 11
12 Drug interactions in Co-infection Drug interactions ddi and d4t plus interferon/ribavirin appear to cause mitochondrial toxicity result: lactic acidosis, peripheral neuropathy Avoid starting these drugs if plan to treat HCV later Clinical manifestations: pancreatitis, hepatitis, myopathy, peripheral neuropathy and lactic acidosis Drug interactions Monitor serum lactate and amylase monthly Consider changing HAART before starting combination therapy Discontinue all meds immediately if lactate rising Treatment Decisions Treat Hep. C first? (if HIV stable, if CD4 count good) Treat HIV first? (if immune compromised) Hepatitis C and HIV/HCV Coinfection 12
13 Sofosbuvir + PEG + RBV: Treatment-Naive HCV GT 1,4,5,6 NEUTRINO Trial: Results NEUTRINO: SVR 12 by Genotype Sofosbuvir + PEG + RBV: Treatment-Naive HCV GT 1,4,5,6 NEUTRINO Trial: Results NEUTRINO: SVR 12 by Race 261/292 27/28 7/7 248/273 47/54 GT = genotype Source: Lawitz E, et al. N Engl J Med. 2013;368: Source: Lawitz E, et al. N Engl J Med. 2013;368: Sofosbuvir + PEG + RBV: Treatment-Naive HCV GT 1,4,5,6 NEUTRINO Trial: Results NEUTRINO: SVR 12 by Liver Disease 252/273 43/54 Sofosbuvir + PEG + RBV: Treatment-Naive HCV GT 1,4,5,6 NEUTRINO Trial: Adverse Events Event SOF + PEG + RBV (n=327) Discontinuation due to adverse event 5 (2%) Fatigue 192 (59%) Headache 118 (36%) Nausea 112 (34%) Rash 59 (18%) Hemoglobin < 10 g/dl 74 (23%) Neutropenia 54 (17%) Influenza-like illness 51 (16%) Depression 31 (9.5%) Insomnia 81 (41%) Rates of adverse events shown in triple therapy did not exceed rates seen in dual therapy (Peg + RBV) arm of FISSION. Source: Lawitz E, et al. N Engl J Med. 2013;368: Source: Lawitz E, et al. N Engl J Med. 2013;368: Hepatitis C and HIV/HCV Coinfection 13
14 Sofosbuvir + PEG + RBV: Treatment-Naive HCV GT 1,4,5,6 NEUTRINO Trial: Conclusions Treatment Naïve Conclusions: In the open-label, single-group study, 12 weeks of treatment with sofosbuvir plus peginterferonribavirin had high efficacy in previously untreated patients with genotype 1 or 4 infection, with apparent reductions in adverse effects. Sofosbuvir + RBV in Treatment-Naïve Genotypes 2,3 FISSION Trial* *Note: Published in NEJM in tandem with NEUTRINO Trial (Genotypes 1,4,5,6) Lawitz E, et al. N Engl J Med. 2013;368: *Note: This conclusion pertains to both the NEUTRINO and FISSION trials, which were published in tandem Source: Lawitz E, et al. N Engl J Med. 2013;368: Sofosbuvir + Ribavirin for Treatment-Naïve HCV GT 2 or 3 FISSION Trial: Features FISSION Trial: Features Design: Randomized, controlled, open-label phase 3 non-inferiority trial comparing sofosbuvir + ribavirin versus PEG + ribavirin in HCV GT 2,3 Setting: 97 sites in US, Australia, New Zealand, Italy, Sweden, and the Netherlands, enrolled Dec 2011-May 2012 Entry Criteria - Treatment-naïve, chronic HCV Genotype 2 or 3 - HCV RNA 10,000 IU/ml Patient Characteristics - N = 499 HCV-monoinfected patients - HCV Genotype: 2 (28%); 3 (72%) - IL28B Genotype: 57% non-cc - Age and Sex: mean age 48 (range 19-77); 66% male - Race: 87% white; 3.4% black - Liver disease: 20% had cirrhosis Primary End-Point: SVR12 Source: Lawitz E, et al. N Engl J Med. 2013;368: Week 0 12 N =256 N =243 Sofosbuvir + Ribavirin for Treatment-Naïve HCV GT 2 or 3 FISSION Trial: Design Sofosbuvir + RBV (weight-based) Peginterferon + RBV (fixed-dose) Source: Lawitz E, et al. N Engl J Med. 2013;368: SVR12 Drug Dosing Sofosbuvir: 400 mg once daily Peginterferon alfa-2a: 180 µg once weekly Weight-based Ribavirin (in 2 divided doses): 1000 mg/day if < 75 kg or 1200 mg/day if 75 kg Fixed-dose Ribavirin (in 2 divided doses): 800 mg/day SVR12 Hepatitis C and HIV/HCV Coinfection 14
15 Sofosbuvir + Ribavirin for Treatment-Naïve HCV GT 2 or 3 FISSION Trial: Results FISSION: HCV RNA <25 IU/ml by Study Timepoint (GT 2, 3 Combined) Sofosbuvir + Ribavirin for Treatment-Naïve HCV GT 2 or 3 FISSION Trial: Results FISSION: SVR12 by Genotype 249/ / / / / / / /243 68/70 52/67 102/ /176 RBV = Ribavirin; PEG = Peginterferon RBV = Ribavirin; PEG = Peginterferon Source: Lawitz E, et al. N Engl J Med. 2013;368: Source: Lawitz E, et al. N Engl J Med. 2013;368: Event Sofosbuvir + Ribavirin for Treatment-Naïve HCV GT 2 or 3 FISSION Trial: Adverse Effects Sofosbuvir + RBV (n=256) PEG + RBV (n=243) Discontinuation due to adverse event 3 (1%) 26 (11%) Fatigue 92 (36%) 134 (55%) Headache 64 (25%) 108 (44%) Nausea 46 (18%) 70 (29%) Pruritus 19 (7%) 42 (17%) Hemoglobin < 10 g/dl 23 (9%) 35 (14%) Neutropenia 0 30 (12%) Influenza-like illness 7 (3%) 43 (18%) Depression 14 (5.5%) 34 (14%) Insomnia 31 (12%) 70 (29%) Source: Lawitz E, et al. N Engl J Med. 2013;368: Sofosbuvir FDA Approved, December 6, 2013 FDA Panel recommended approval October 25, 2013 Recommendation covers both use with interferon-based therapy for treatment-naive people with HCV genotypes 1 or 4 Also use in dual therapy with ribavirin for people with easier-to-treat HCV genotypes 2 or 3 - the first approved interferon-free regimen Gilead Sciences. FDA Advisory Committee Supports Approval of Gilead s Sofosbuvir for Chronic Hepatitis C Infection. Press release. October 25, Accessed June 4, Hepatitis C and HIV/HCV Coinfection 15
16 Sofosbuvir Key Points Indication NS5B nucleotide polymerase inhibitor for the treatment of chronic HCV as a component of combination anitiviral treatment regimen 400 mg tablet, once daily dosing, with no food restrictions HCV Mono-infected and HCV/HIV Co-infected Genotype 1 or 4 Treatment Sofosbuvir + PEGinterferon + ribavirin Duration 12 weeks Genotype 2 Sofosbuvir + ribavirin 12 weeks Genotype 3 Sofosbuvir + ribavirin 24 weeks Sofosbuvir Key Points Sofosbuvir + ribavirin ALONE for 24 weeks can be considered for GT1 if intolerant to interferon No dosage recommendation can be made in patients with severe renal impairment or ESRD up to 20 fold increase in SOF metabolite Contraindications Monotherapy, also ribavirin birth defects Accessed June 4, Accessed June 4, Sofosbuvir Key Points Adverse Events Headache and fatigue most common Anemia and insomnia, nausea when adding peginterferon + ribavirin Additional info HIV/HCV coinfection studied, also data on patients with HCC awaiting liver transplantation studied Drug Interactions Intestinal PGP inducers likely to reduce levels ie rifampin, St Johns Wort Accessed June 4, 2014 PHOTON-1 Trial in HIV/HCV Co-infection Open-label, phase 3 study of sofosbuvir plus weightbased ribavirin in coinfection, genotypes 1, 2 or 3. GT1, Naive GT2/3, Naive GT2/3, Experienced Week SOF + RBV, n=114 SOF + RBV, n=68 SOF + RBV, n=41 Naggie S et al. CROI 2014; Abst 26. SVR 12 SVR Hepatitis C and HIV/HCV Coinfection 16
17 PHOTON-1: Results PHOTON-1: Results Allowable ARVs: NRTIs, atazanavir/r, darunavir/r, rilpivirine & raltegravir Most virologic failures had relapse No sofosbuvir resistance seen Naggie S et al. CROI 2014; Abst Naggie S et al. CROI 2014; Abst Patients, % AEs PHOTON-1 Adverse Events 24 Weeks SOF+RBV(n=155) 12 Weeks SOF+RBV(n=68) Fatigue Insomnia Headache Nausea Diarrhea 11 9 Irritability URI Grade 3-4 AEs Serious AEs 6 7 Treatment DC due to AEs 3 4 Death 0 1 Medications to Avoid with Sofosbuvir Medication and or Class Rationale for Avoiding with Sofosbuvir Anticonvulsants carbamazepine, oxcarbazepine, Co-administration with these medications is likely to reduce concentrations of sofosbuvir leading to reduced sofosbuvir efficacy. Co-administration not recommended. phenobarbital, phenytoin Antimycobacterials Co-administration with these medications is likely to reduce rifampin, rifabutin, rifapentin concentrations of sofosbuvir leading to reduced sofosbuvir efficacy due to intestinal P-glycoprotein (P-gp) induction from rifampin. Herbal products St. John s Wort Co-administration with these medications is likely to reduce concentrations of sofosbuvir leading to reduced sofosbuvir efficacy due to intestinal P-glycoprotein (P-gp) induction associated with St. John s Wort. Naggie S et al. CROI 2014; Abst Hepatitis C and HIV/HCV Coinfection 17
18 Sofosbuvir and HIV Medications Sofosbuvir and HIV Medications Concurrent Medication Recommendation HIV Protease Inhibitors All HIV PIs, with or without ritonavir, except Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of sofosbuvir. tipranavir Tipranavir (Aptivus ) Co administration not recommended HIV Non Nucleoside Reverse Transcriptase Inhibitors All NNRTIs Concurrent use at standard doses acceptable. Concurrent Medication Recommendation HIV Integrase Strand Transfer Inhibitors Dolutegravir (Tivicay ) Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of sofosbuvir. Elvitegravir (contained in Stribild ) Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of sofosbuvir. Raltegravir (Isentress ) Concurrent use at standard doses acceptable. HIV Entry Inhibitors Maraviroc (Selzentry ) Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of sofosbuvir. HIV Nucleoside/Nucleotide Reverse Transcriptase Inhibitors All NRTIs Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of sofosbuvir. HIV/HCV Co-Infection, GT1 Preferred Treatment-naïve, prior PEG/RBV relapsers, IFN eligible: SOF + PEG/RBV(WB) x 12 weeks IFN ineligible: SOF + RBV(WB) x 24 weeks SOF + SMV ± RBV(WB) x 12 weeks Treatment experienced, prior PEG/RBV nonresponders, regardless of IFN eligibility: SOF + SMV ± RBV(WB) x 12 weeks Alternative Treatment-naïve, prior PEG/RBV relapsers, IFN eligible: SMV x 12 weeks + PEG/RBV(WB) x 24 weeks IFN ineligible: None Treatment experienced, prior PEG/RBV nonresponders IFN eligible: SOF + PEG/RBV(WB) x 12 Weeks IFN ineligible: SOF + RBV(WB) x 24 Weeks Not Recommended: TVR + PEG/RBV x 24 or 48 weeks (RGT), BOC + PEG/RBV x 28 or 48 weeks (RGT) PEG/RBV 48 k SMV 12 k + PEG/RBV 48 k Hepatitis C and HIV/HCV Coinfection 18
19 Preferred HIV/HCV Co-Infection, GT2 All patients, regardless of treatment history: SOF + RBV(WB) x 12 weeks Alternative Treatment naive and prior PEG/RBV relapsers: None Treatment experienced, prior PEG/RBV Nonresponders: IFN eligible: SOF + PEG/RBV(WB) X 12 Weeks IFN ineligible: None Not Recommended: PEG/RBV x weeks, or any regimen with TVR, BOC, or SMV HIV/HCV Co-Infection, GT3 Preferred All patients, regardless of treatment history: SOF + RBV(WB) x 24 weeks Alternative Treatment naïve, PEG/RBV relapsers: None Treatment experienced, prior PEG/RBV Nonresponders: IFN eligible: SOF + PEG/RBV(WB) X 12 weeks IFN ineligible: None Not Recommended: PEG/RBV x weeks, Any regimen with TVR, BOC, or SMV HIV/HCV Coinfection, GT4 Preferred All patients, regardless of treatment history: IFN eligible: SOF + PEG/RBV(WB) x 12 weeks Alternative None IFN ineligible: SOF + RBV(WB) x 24 weeks Not Recommended: PEG/RBV x 48 weeks, any regimen with TVR or BOC HIV/HCV Coinfection, GT 5,6 Preferred All patients, regardless of treatment history: SOF + PEG/RBV(WB) x 12 weeks Alternative None Not Recommended: PEG/RBV x 48 weeks, any regimen with TVR, BOC, or SMV Hepatitis C and HIV/HCV Coinfection 19
20 Simeprevir and HIV Medications Simeprevir and HIV Medications Concurrent Medication Recommendation HIV Protease Inhibitors All HIV PIs Significant increases or decreases in simeprevir levels expected when used with any HIV protease inhibitor, when used with or without ritonavir. Co-administration not recommended HIV Non Nucleoside Reverse Transcriptase Inhibitors Efavirenz (Sustiva ), Etravirine (Intelence ), Nevirapine (Viramune ) Significant reductions in simeprevir levels and reduced simeprevir efficacy due to CYP3A4 induction. Coadministration not recommended. Rilpivirine (Edurant ) Concurrent use at standard doses acceptable. Concurrent Medication Recommendation HIV Integrase Strand Transfer Inhibitors Dolutegravir (Tivicay ) Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of simeprevir. Elvitegravir (contained in Stribild ) Significant increase in simeprevir levels expected when used with a cobicistat containing regimen. Co-administration not recommended. Raltegravir (Isentress ) Concurrent use at standard doses acceptable. HIV Entry Inhibitors Maraviroc (Selzentry ) Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of simeprevir. HIV Nucleoside/Nucelotide Reverse Transcriptase Inhibitors All NRTIs Concurrent use at standard doses acceptable. Interactions not expected based upon metabolism of simeprevir. Standard Dosing Sofosbuvir 400mg once daily Simeprevir 150mg once daily Peg Interferon 180mcg once weekly Ribavirin weight based dosing <75kg 1000mg daily in divided doses 75 kg 1200mg daily in divided doses IFN Ineligible Definitions Intolerance to IFN Autoimmune hepatitis and other autoimmune disorders Hypersensitivity to PEG or any of its components Decompensated hepatic disease History of depression, or clinical features consistent with depression A baseline neutrophil count below 1500/μL, a baseline platelet count below 90,000/μL or baseline hemoglobin below 10 g/dl A history of preexisting cardiac disease Hepatitis C and HIV/HCV Coinfection 20
21 Summary SVR was significantly higher for PEGASYS (40 kda) + COPEGUS compared to conventional combination therapy Overall: 40% vs 12%; P < Genotype 1: 29% vs 7% Genotype 2/3: 62% vs 20% Adverse event profile of PEGASYS (40kDa) + COPEGUS is generally similar to IFN + RBV therapy Only 15% of patients discontinued for adverse events or laboratory abnormalities Hepatitis C/HIV SUMMARY HIV+ persons have worse liver disease Treatment should be considered Expect greater side effects, possible interactions with HIV medications Clinical Pearls for the Pharmacist Special tests: abdominal ultrasounds/egd/liver biopsy Combination therapy management Vaccinations: HAV, HBV, pneumovax? Education Team Work Physician/PA/NP providers Nutritionists Social workers/case Managers Mental health: psychiatrist/counselors Pharmacists Hepatitis C and HIV/HCV Coinfection 21
22 Questions Hepatitis C and HIV/HCV Coinfection 22
Updated Guidelines for Managing HIV/HCV Co-Infection
Updated Guidelines for Managing HIV/HCV Co-Infection John J Faragon, PharmD, BCPS, AAHIV-P Regional Pharmacy Director, NY/NJ AIDS Education and Training Center Pharmacist, HIV Medicine, Albany Medical
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were
More informationUpdate on Real-World Experience With HARVONI
Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationHepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011
Hepatitis C Update Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011 Outline n Educational Objectives Epidemiology and Natural History of Hepatitis C Current Treatment
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationA Practical Guide to Hepatitis C Management
A Practical Guide to Hepatitis C Management David C. Wolf, M.D., FACP, FACG, AGAF Medical Director of Liver Transplantation Westchester Medical Center Professor of Clinical Medicine New York Medical College
More informationParent drug: hours. Not reported Parent drug: 0.4 hours Major metabolite (GS ): 27 hours. ~61% to 65% bound to human plasma proteins
Brand Name: Sovaldi Generic Name: sofosbuvir Manufacturer 3 : Gilead Sciences Inc. Drug Class 1,2 : Antiinfective, Antihepaciviral, Anti-HCV, NS5B polymerase inhibitor Uses: Labeled 1,2,3,4,5 : Chronic
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationCommonly Asked Questions About Chronic Hepatitis C
Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationHEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014
HEPATITIS C UPDATES Sanaa S. Said 10 th April, 2014 CONTENTS Introduction Epidemiology Transmission and Natural history Kenyan guidelines What is new? References INTRODUCTION Hepacivirus genus, Flaviviridae
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationPegylated Interferon Agents for Hepatitis C
Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection
More informationHepatitis C Virus Clinical Criteria Update September 18, For: New York State Medicaid
Hepatitis C Virus Clinical Criteria Update September 18, 2014 For: New York State Medicaid 1 Purpose Characterize the place in therapy for the agents utilized for management of chronic hepatitis C (CHC)
More informationSovaldi Ribavirin. Sovaldi (sofosbuvir) with Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Sovaldi Ribavirin Page: 1 of 7 Last Review Date: December 3, 2015 Sovaldi Ribavirin Description
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationBruce A. Luxon, MD, Ph.D. Anton and Margaret Fuisz Chair in Medicine Professor and Chair Department of Medicine Georgetown University
Bruce A. Luxon, MD, PhD, FACG Bruce A. Luxon, MD, Ph.D. Anton and Margaret Fuisz Chair in Medicine Professor and Chair Department of Medicine Georgetown University Dr. Luxon is on the speakers p bureau
More informationBrief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV)
Brief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV) James Morrill, MD, PhD MGH Charlestown HealthCare Center Massachusetts General Hospital www.mghcme.org Disclosures Neither
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationHIV and HCV Drug Interactions Cased Based Discussion. John J. Faragon, PharmD, BCPS, AAHIV-P. Brief background on HCV and HIV Coinfection
HIV and HCV Drug Interactions Cased Based Discussion John J. Faragon, PharmD, BCPS, AAHIV-P Roadmap Brief background on HCV and HIV Coinfection Revised AASLD Guidelines Case evaluating drug interactions
More informationInfergen (interferon alfacon-1) with Ribavirin (Copegus, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.04 Subject: Infergen with Ribavirin Page: 1 of 8 Last Review Date: March 13, 2014 Infergen with Ribavirin
More informationDevelopments in the Treatment of Hepatitis C: A New Era
Developments in the Treatment of Hepatitis C: A New Era Nancy Love, PharmD, BCPS Memorial Medical Center, Johnstown, PA October 17, 2014 Pharmacist Objectives Summarize the results of clinical trials for
More informationHepatits C Criteria Direct Acting Antiviral Medications
Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationSovaldi (sofosbuvir) with PegIntron (peginterferon alfa-2b) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.24 Subject: Sovaldi PegIntron Ribavirin Page: 1 of 6 Last Review Date: November 30, 2018 Sovaldi PegIntron
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationSovaldi (sofosbuvir) with Pegasys (peginterferon alfa-2a) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.25 Subject: Sovaldi Pegasys Ribavirin Page: 1 of 6 Last Review Date: December 8, 2017 Sovaldi Pegasys
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationJOHNS HOPKINS HEALTHCARE
JOHNS HOPKINS HEALTHCARE Subject: Clinical Criteria for Hepatitis C (HCV) Therapy Department: Pharmacy Lines of Business: PPMCO Policy Number: MEDS92 Effective Date: 04/15/2015 Revision Date: 08/15/2015
More informationBible Class: HCV Infection
Bible Class: HCV Infection PD Dr. Dr. med. Nasser Semmo UVCM, Hepatology What is the HCV prevalence and incidence? 2 HCV Prevalence Worldwide about 120-210 Mio. infected with HCV, about 9 Mio. in Europe,
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationA "State-of-the-Art" Conference Hepatitis C: A Meeting Ground for the Generalist and the Specialist
A "State-of-the-Art" Conference Hepatitis C: A Meeting Ground for the Generalist and the Specialist Information regarding pathogenesis and appropriate management of chronic hepatitis C continues to evolve.
More informationUPDATES IN HEPATITIS C
UPDATES IN HEPATITIS C S A R A H N A I D O O, P H A R M, B C P S AP RI L 13, 2014 OBJECTIVES Be able to discuss changes in hepatitis c treatment Be able to provide recommendations to providers regarding
More informationSOFOSBUVIR/VELPATASVIR Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR
Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR EPCLUSA 43561 GUIDELINES FOR USE 1. Is the patient at least 18 years old? If yes, continue to #2. 2. Does the patient have a diagnosis of
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationChronic Hepatitis C. Risk Factors
Chronic Hepatitis C The hepatitis C virus is one of the most important causes of chronic liver disease in the United States. Almost 4 million Americans or 1.8 percent of the U.S. population have an antibody
More informationHarvoni (sofosbuvir/ledipasvir
Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationHepatitis C: Let s Talk About It. Causes of Hepatitis
Hepatitis C: Let s Talk About It Susan Thompson, RN, MPH Technical Assistance and Training Program NC Communicable Disease Branch July 2012 Causes of Hepatitis any swelling, inflammation, or irritation
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationIntron A (interferon alfa-2b) with ribavirin, (Moderiba, Rebetol, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.06 Subject: Intron A Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Intron A Ribavirin Description
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationInfergen Monotherapy. Infergen (interferon alfacon-1) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.03 Subject: Infergen Monotherapy Page: 1 of 7 Last Review Date: March 13, 2014 Infergen Monotherapy
More informationSovaldi (sofosbuvir)
Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid
More informationOmbitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak) Prepared by: Sophie Woolston, MD and David H. Spach, MD Last Updated: December 29, 2014 OMBITASVIR-PARITAPREVIR-RITONAVIR
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More informationConsiderations for the management of Hepatitis C in patients with HIV co-infection
Considerations for the management of Hepatitis C in patients with HIV co-infection Marcella Honkonen, PharmD, BCPS Sunday, February 22, 2012 at 10:15 AM AzPA Southwest Clinical Conference JW Marriott,
More informationREQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments
Fax completed form to: 866-940-7328 Prior Authorization Phone Number: 800-310-6826 IA Medicaid Member ID # Patient name Date of Birth Patient address Patient phone Provider NPI Prescriber name Phone Prescriber
More informationTreatment of Chronic Hepatitis C in HIV infection
Treatment of Chronic Hepatitis C in HIV infection June 25, 211 Andrew Talal, MD, MPH Associate Professor of Medicine Associate Medical Director Center for the Study of Hepatitis C Weill Cornell Medical
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationHepatitis C Genotype 1 (GT 1) Patients in the United States (US)
Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) INDICATION is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 8 Last Review Date: December 18, 2017 Olysio Pegasys
More informationCurrent Therapies for Chronic Hepatitis C
Southern Illinois University Edwardsville SPARK Pharmacy Faculty Research, Scholarship, and Creative Activity School of Pharmacy 1-2011 Current Therapies for Chronic Hepatitis C McKenzie C. Ferguson Southern
More informationTreatment with the New Direct Acting Antivirals for Hepatitis C
Treatment with the New Direct Acting Antivirals for Hepatitis C Mary Olson, DNP, ANP-BC Clinical Trials Program Director Weill Cornell Medical College The Center for the Study of Hepatitis C Objectives
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationIntron A (interferon alfa-2b) with ribavirin, (Copegus, Moderiba, Rebetol, Ribapak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Intron A Ribavirin Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Ribavirin Description
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationDescription of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases
Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis B / Hepatitis C Peg-interferon Page 1 of 20 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis B / Hepatitis C Peg-interferon Hepatitis
More informationJanuary 2008 IMPORTANT DRUG WARNING
January 2008 IMPORTANT DRUG WARNING Dear Healthcare Professional: Roche would like to advise you of a recent update to the PEGASYS (Peginterferon alfa-2a) and COPEGUS (Ribavirin, USP) package inserts.
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other TELAPREVIR INCIVEK 37629 This drug requires a written request for prior authorization. All requests for hepatitis C medications require review by a pharmacist prior
More informationOlysio PegIntron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.27 Subject: Olysio PegIntron Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio PegIntron
More informationCurrent State of Treatment for HCV. Nancy Reau, MD Associate Professor of Medicine University of Chicago
Activity Code FA376 Current State of Treatment for HCV Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives Upon completion of this presentation, learners should be
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationPegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience
Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More information